China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer Abogen Biosciences Co., Ltd to develop lipid nanoparticles (LNPs) for mRNA delivery targeting retinal diseases. The collaboration combines Neurophth’s expertise in ophthalmology gene therapy with Abogen’s mRNA and LNP technology.
Partnership Details
The partnership aims to create novel mRNA therapies for retinal conditions, leveraging Neurophth’s gene therapy platform and Abogen’s mRNA/LNP expertise. Financial terms were not disclosed.
Company Backgrounds
- Abogen Biosciences: Developed China’s first homegrown COVID-19 mRNA vaccine, currently in Phase III trials since June 2020, with a manufacturing license granted in November 2023.
- Neurophth Biotechnology: Focuses on ophthalmology gene therapy. Its lead product NR082 (rAAV2-ND4, NFS-01) received US Orphan Drug Designation for ND4-mediated Leber hereditary optic neuropathy (ND4-LHON). The pipeline includes candidates for ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, and vascular retinopathy.-Fineline Info & Tech
